Spectrum To Confer With FDA On Cancer Drug Approval Delay
Spectrum Pharmaceuticals Inc. plans to discuss with U.S. Food and Drug Administration officials why the agency has held off on approving its drug Evomela for treating multiple myeloma, a form of...To view the full article, register now.
Already a subscriber? Click here to view full article